The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in lewy body disease

Journal of Alzheimer's Disease

Volumn 19, Issue 3, 2010, Pages 937-942

  Maetzler, Walter ^a,b   Schmid, Benjamin ^a   Synofzik, Matthis ^a   Schulte, Claudia ^a   Riester, Karin ^a   Huber, Heiko ^a   Brockmann, Kathrin ^a   Gasser, Thomas ^a   Berg, Daniela ^a   Melms, Arthur ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Amyloid; Amyloidosis; CST3 gene; Dementia with Lewy bodies; Parkinson's disease

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CYSTATIN C;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; CST3 BB GENE; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FEMALE; GENE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 77149165424     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1289     Document Type: Article

References (35)

1. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK (2007) DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68, 812-819.
2. Cummings JL (1988) Intellectual impairment in Parkinson's disease: clinical, pathologic, and biochemical correlates. J Geriatr Psychiatry Neurol 1, 24-36.
3. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 60, 387-392.
4. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Nagren K, Chaudhury KR, Masters CL, Brooks DJ (2008) Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79, 1331-1338.
5. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW (2002) Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 59, 102-112.
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24, 197-211.
7. Hughes AJ, Daniel SE, Blankson S, Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 50, 140-148.
8. Jellinger KA, Seppi K,Wenning GK (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 106, 188-189; author reply 190.
9. Leech RW, Brumback RA, Poduslo SE, Schiffer R, Adesina A (2001) Dementia: the University of Oklahoma autopsy experience. J Okla State Med Assoc 94, 507-511.
10. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D (2009) Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34, 107-112.
11. Nishio C, Yoshida K, Nishiyama K, Hatanaka H, Yamada M (2000) Involvement of cystatin C in oxidative stress-induced apoptosis of cultured rat CNS neurons. Brain Res 873, 252-262.
12. Grubb A (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38 Suppl 1, S20-27.
13. Pierre P, Mellman I (1998) Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 93, 1135-1145.
14. Finckh U, von der Kammer H,Velden J, Michel T, Andresen B, Deng A, Zhang J, Muller-Thomsen T, Zuchowski K, Menzer G, Mann U, Papassotiropoulos A, Heun R, Zurdel J, Holst F, Benussi L, Stoppe G, Reiss J, Miserez AR, Staehelin HB, Rebeck GW, Hyman BT, Binetti G, Hock C, Growdon JH, Nitsch RM (2000) Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol 57, 1579-1583.
15. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A (2007) Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest 67, 179-190.
16. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, Schmidt SD, Nixon RA, Frangione B, Levy E (2004) Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25, 1033-1043.
17. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML,Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39, 1437-1439.
18. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, Levy E (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39, 1440-1442.
19. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16, 389-397.
20. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, Vassilopoulos D, Waldemar G (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24, 434-440.
21. Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia. Acta Neurol Scand 101, 279-282.
22. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez JC (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494. (Pubitemid 37048074)
23. Benussi L, Ghidoni R, Steinhoff T, Alberici A, Villa A, Mazzoli F, Nicosia F, Barbiero L, Broglio L, Feudatari E, Signorini S, Finckh U, Nitsch RM, Binetti G (2003) Alzheimer diseaseassociated cystatin C variant undergoes impaired secretion. Neurobiol Dis 13, 15-21.
24. Paraoan L, Ratnayaka A, Spiller DG, Hiscott P, White MR, Grierson I (2004) Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic 5, 884-895.
25. Beyer K, Lao JI, Gomez M, Riutort N, Latorre P, Mate JL, Ariza A (2001) Alzheimer's disease and the cystatin C gene polymorphism: an association study. Neurosci Lett 315, 17-20.
26. Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE (2005) Cystatin C as a risk factor for Alzheimer disease. Neurology 64, 755-757.
27. Crawford FC, Freeman MJ, Schinka JA, Abdullah LI, Gold M, Hartman R, Krivian K, Morris MD, Richards D, Duara R, Anand R, Mullan MJ (2000) A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 55, 763-768.
28. Chuo LJ, Sheu WH, Pai MC, Kuo YM (2007) Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 23, 251-257.
29. Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young-and old-onset Parkinson's disease. Neurology 38, 1402-1406.
30. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65, 1863-1872.
31. Mi W, Jung SS, Yu H, Schmidt SD, Nixon RA, Mathews PM, Tagliavini F, Levy E (2009) Complexes of amyloid-beta and cystatin C in the human central nervous system. J Alzheimers Dis 18, 273-280.
32. Levy E, Sastre M, Kumar A, Gallo G, Piccardo P, Ghetti B, Tagliavini F (2001) Codeposition of cystatin C with amyloidbeta protein in the brain of Alzheimer disease patients. J Neuropathol Exp Neurol 60, 94-104.
33. Lofberg H, Grubb AO (1979) Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. Scand J Clin Lab Invest 39, 619-626.
34. Nagai A, Terashima M, Sheikh AM, Notsu Y, Shimode K, Yamaguchi S, Kobayashi S, Kim SU, Masuda J (2008) Involvement of cystatin C in pathophysiology of CNS diseases. Front Biosci 13, 3470-3479.
35. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Gan L (2008) Cystatin Ccathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60, 247-257.